The Latin America, Middle East and Africa Renal Denervation Market is expected to witness market growth of 42.0% CAGR during the forecast period (2022-2028).
Resistance hypertension requires four or more antihypertensive medicines to maintain blood pressure below 130/80 mmHg. RH is a rapidly increasing clinical disease that is linked to target-organ damage and a poor prognosis when compared to non-RH patients. Renal denervation therapy for RH had a complex history over the few years, ranging from exuberant enthusiasm to abrupt disillusionment, and now a renewed but cautious interest. Major Market players are analyzing typical clinical trials of RH addressed with RDN in previous years and determined that RDN therapy appears to be safer and more dependable for RH. Moreover, the potential functions of RDN are still being reviewed in clinical practices and appear to have validated the benefits of RDN on long-term results in RH patients. Resistant hypertension is characterized as high blood pressure despite using at least three antihypertensive drugs from various classes, one of which is a diuretic.
As per the data shared by the Abu Dhabi's Department of Health, cardiovascular disease is the top cause of mortality among Abu Dhabi's population. This has not improved over time, despite the enormous commitment of time and resources. Over 39 percent of deaths in people over 45 years old were due to cardiovascular disease. CVD kills more people over the age of 60 than cancer, respiratory disorders, and infectious diseases combined. A poor diet is the major cause of CVD mortality, with one study estimating that the current diet was responsible for 72 percent of CVD deaths in the United Arab Emirates. In the United Arab Emirates, low consumption of whole grains was linked to 22% of CVD-related deaths. Consumption of red meat, processed meat, and sugar-sweetened beverages are further risk factors.
The Brazil Market dominated the LAMEA Renal Denervation Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $25.6 million by 2028. The Argentina Market is estimated to grow a CAGR of 42.8% during (2022-2028). Additionally, The UAE Market is expected to exhibit a CAGR of 41.7% during (2022-2028).
Based on Technology, the Market is segmented into Radiofrequency, Ultrasound, and Micro-Infusion. Based on End User, the Market is segmented into Hospitals, Specialty Clinics, and Others. Based on Product Type, the Market is segmented into Symplicity, Enlightn, Vessix, Paradise, Iberis, and Others. Based on countries, the Market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Ablative Solutions, Inc., Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, Johnson & Johnson, and Terumo Corporation.
By Technology
By Country
Resistance hypertension requires four or more antihypertensive medicines to maintain blood pressure below 130/80 mmHg. RH is a rapidly increasing clinical disease that is linked to target-organ damage and a poor prognosis when compared to non-RH patients. Renal denervation therapy for RH had a complex history over the few years, ranging from exuberant enthusiasm to abrupt disillusionment, and now a renewed but cautious interest. Major Market players are analyzing typical clinical trials of RH addressed with RDN in previous years and determined that RDN therapy appears to be safer and more dependable for RH. Moreover, the potential functions of RDN are still being reviewed in clinical practices and appear to have validated the benefits of RDN on long-term results in RH patients. Resistant hypertension is characterized as high blood pressure despite using at least three antihypertensive drugs from various classes, one of which is a diuretic.
As per the data shared by the Abu Dhabi's Department of Health, cardiovascular disease is the top cause of mortality among Abu Dhabi's population. This has not improved over time, despite the enormous commitment of time and resources. Over 39 percent of deaths in people over 45 years old were due to cardiovascular disease. CVD kills more people over the age of 60 than cancer, respiratory disorders, and infectious diseases combined. A poor diet is the major cause of CVD mortality, with one study estimating that the current diet was responsible for 72 percent of CVD deaths in the United Arab Emirates. In the United Arab Emirates, low consumption of whole grains was linked to 22% of CVD-related deaths. Consumption of red meat, processed meat, and sugar-sweetened beverages are further risk factors.
The Brazil Market dominated the LAMEA Renal Denervation Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $25.6 million by 2028. The Argentina Market is estimated to grow a CAGR of 42.8% during (2022-2028). Additionally, The UAE Market is expected to exhibit a CAGR of 41.7% during (2022-2028).
Based on Technology, the Market is segmented into Radiofrequency, Ultrasound, and Micro-Infusion. Based on End User, the Market is segmented into Hospitals, Specialty Clinics, and Others. Based on Product Type, the Market is segmented into Symplicity, Enlightn, Vessix, Paradise, Iberis, and Others. Based on countries, the Market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Ablative Solutions, Inc., Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, Johnson & Johnson, and Terumo Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Radiofrequency
- Ultrasound
- Micro-Infusion
- Hospitals
- Specialty Clinics
- Others
- Symplicity
- Enlightn
- Vessix
- Paradise
- Iberis
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic PLC
- Ablative Solutions, Inc.
- Mercator MedSystems, Inc.
- ReCor Medical, Inc.
- Renal Dynamics Limited
- Johnson & Johnson
- Terumo Corporation
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Renal Denervation Market by Technology
Chapter 4. LAMEA Renal Denervation Market by End User
Chapter 5. LAMEA Renal Denervation Market by Product Type
Chapter 6. LAMEA Renal Denervation Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic PLC
- Ablative Solutions, Inc.
- Mercator MedSystems, Inc.
- ReCor Medical, Inc.
- Renal Dynamics Limited
- Johnson & Johnson
- Terumo Corporation
Methodology
LOADING...
